Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
Pathological type, liver metastasis, brain metastasis, NSE, and CYFRA 21 - 1 were identified as independent risk factors for stage IV NSCLC patients treated with EGFR-TKIs, while chemotherapy and radiotherapy were determined to be independent protective factors. Taking icotinib or gefitinib, as opposed to osimertinib, was an independent risk factor for advanced NSCLC patients.
Authors
- Yangkai Li (ORCID: https://orcid.org/0000-0001-5342-5078)
- Linwu Kuang
- Peng Wang (ORCID: https://orcid.org/0000-0003-4972-1231)
- Yuchen Zhang (ORCID: https://orcid.org/0000-0003-3378-1520)
- Hao Wang (ORCID: https://orcid.org/0000-0002-2438-6732)
Institutions
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1186/s12890-025-03569-1
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07